CN112236161A - G蛋白偶联受体的调节剂 - Google Patents

G蛋白偶联受体的调节剂 Download PDF

Info

Publication number
CN112236161A
CN112236161A CN201980032743.8A CN201980032743A CN112236161A CN 112236161 A CN112236161 A CN 112236161A CN 201980032743 A CN201980032743 A CN 201980032743A CN 112236161 A CN112236161 A CN 112236161A
Authority
CN
China
Prior art keywords
group
independently selected
compound
ring
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980032743.8A
Other languages
English (en)
Chinese (zh)
Inventor
J·因奎斯特
S·克里斯南
S·阿特瓦
D·厄兰松
R·V·弗悉尼
S·汉森
A·沙瓦亚麻
S·瑟斯弗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Carmot Therapeutics Inc
Original Assignee
Carmot Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Carmot Therapeutics Inc filed Critical Carmot Therapeutics Inc
Publication of CN112236161A publication Critical patent/CN112236161A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CN201980032743.8A 2018-03-23 2019-03-22 G蛋白偶联受体的调节剂 Pending CN112236161A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862647604P 2018-03-23 2018-03-23
US62/647,604 2018-03-23
PCT/US2019/023726 WO2019183577A1 (en) 2018-03-23 2019-03-22 Modulators of g-protein coupled receptors

Publications (1)

Publication Number Publication Date
CN112236161A true CN112236161A (zh) 2021-01-15

Family

ID=67986596

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980032743.8A Pending CN112236161A (zh) 2018-03-23 2019-03-22 G蛋白偶联受体的调节剂

Country Status (18)

Country Link
US (3) US11535660B1 (cg-RX-API-DMAC10.html)
EP (1) EP3768294A4 (cg-RX-API-DMAC10.html)
JP (2) JP7526716B2 (cg-RX-API-DMAC10.html)
KR (2) KR102960848B1 (cg-RX-API-DMAC10.html)
CN (1) CN112236161A (cg-RX-API-DMAC10.html)
AR (1) AR115016A1 (cg-RX-API-DMAC10.html)
AU (2) AU2019237507B2 (cg-RX-API-DMAC10.html)
BR (1) BR112020019148A2 (cg-RX-API-DMAC10.html)
CA (1) CA3094820A1 (cg-RX-API-DMAC10.html)
EA (1) EA202092269A1 (cg-RX-API-DMAC10.html)
IL (3) IL277495B2 (cg-RX-API-DMAC10.html)
MX (2) MX2020009950A (cg-RX-API-DMAC10.html)
MY (1) MY205468A (cg-RX-API-DMAC10.html)
PH (1) PH12020551539A1 (cg-RX-API-DMAC10.html)
SG (1) SG11202009338SA (cg-RX-API-DMAC10.html)
TW (2) TW202444405A (cg-RX-API-DMAC10.html)
UA (1) UA129084C2 (cg-RX-API-DMAC10.html)
WO (1) WO2019183577A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024217497A1 (en) * 2023-04-21 2024-10-24 The University Of Hong Kong Novel small molecule agonists of insulin receptor (insr) as anti-diabetes drugs

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020009950A (es) * 2018-03-23 2021-04-28 Carmot Therapeutics Inc Moduladores de receptores acoplados a proteina g.
JP7688891B2 (ja) * 2021-01-18 2025-06-05 国立大学法人東海国立大学機構 ペプチド
KR20240118914A (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
KR20240007251A (ko) * 2021-05-13 2024-01-16 카모트 테라퓨틱스, 인크. G-단백질 결합 수용체의 조절제
CA3231953A1 (en) 2021-09-15 2023-03-23 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
KR102703958B1 (ko) 2021-11-01 2024-09-09 국민대학교 산학협력단 글루카곤 유사 펩타이드-1 수용체의 양성 알로스테릭 조절제의 스크리닝 방법 및 그 방법에 따라 스크리닝된 글루카곤 유사 펩타이드-1 수용체의 양성 알로스테릭 조절제
WO2024033374A1 (en) 2022-08-11 2024-02-15 Syngenta Crop Protection Ag Novel arylcarboxamide or arylthioamide compounds
WO2024089216A1 (en) 2022-10-27 2024-05-02 Syngenta Crop Protection Ag Novel sulfur-containing heteroaryl carboxamide compounds
US12473382B2 (en) 2022-11-04 2025-11-18 Lg Chem, Ltd. Hologram recording medium and optical element comprising the same
US20250298372A1 (en) * 2022-11-04 2025-09-25 Lg Chem, Ltd. Hologram recording medium and optical element comprising the same
KR20240064272A (ko) * 2022-11-04 2024-05-13 주식회사 엘지화학 불소계 화합물, 광중합성 조성물, 홀로그램 기록 매체, 이의 제조 방법 및 이를 포함하는 광학 소자
JP2026500298A (ja) 2022-12-15 2026-01-06 シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト 殺有害生物剤として有用である新規な二環式カルボキサミド化合物
IL325257A (en) * 2023-06-22 2026-02-01 Carmot Therapeutics Inc Synthesis of GLP-1R/GIPR agonists and their starting materials
EP4777197A2 (en) 2023-09-14 2026-07-22 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
WO2025109387A1 (en) 2023-11-24 2025-05-30 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
TW202615099A (zh) * 2024-07-31 2026-04-16 美商卡默療法股份有限公司 Glp—1r/gipr促效劑之合成
TW202620036A (zh) 2024-09-27 2026-05-16 美商卡默療法股份有限公司 肽酪胺酸-酪胺酸(pyy)類似物及glp-1r促效劑之組合療法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101420941A (zh) * 2006-04-11 2009-04-29 艾尼纳制药公司 Gpr119受体激动剂用于增加骨质量和用于治疗骨质疏松症的用途,和其相关组合疗法
CN102159566A (zh) * 2008-07-16 2011-08-17 百时美施贵宝公司 作为gpr119调节剂的吡啶酮和哒嗪酮类似物
WO2014074218A1 (en) * 2012-11-12 2014-05-15 Redwood Bioscience, Inc. Compounds and methods for producing a conjugate
CN105219802A (zh) * 2015-10-10 2016-01-06 广西大学 胰岛组织特异性表达GIPRdn慢病毒载体及其应用
US20170326233A1 (en) * 2014-11-14 2017-11-16 Angiochem Inc. Conjugates including an antibody moiety, a polypeptide that traverses the blood-brain barrier, and a cytotoxin

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1072649C (zh) 1995-09-13 2001-10-10 武田药品工业株式会社 苯并氧杂吖庚因化合物,其生产方法和用途
US6432947B1 (en) 1997-02-19 2002-08-13 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
AU2610899A (en) * 1998-02-27 1999-09-15 Novo Nordisk A/S N-terminally modified glp-1 derivatives
EP1137667B1 (en) * 1998-12-07 2004-11-17 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Analogues of glp-1
CN1364167A (zh) 1999-02-26 2002-08-14 阿瑞那制药公司 G蛋白偶联受体6的小分子调节剂
EP1235618A2 (en) 1999-09-07 2002-09-04 Conjuchem, Inc. Bioconjugation in vivo to pulmonary or blood components
EP1302462A4 (en) 2000-07-17 2007-07-18 Takeda Pharmaceutical SULFONATE DERIVATIVES, PROCESS FOR PRODUCTION AND USE THEREOF
BR0315815A (pt) 2002-11-01 2005-09-13 Takeda Pharmaceutical Agentes para prevenir ou tratar neuropatia, para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor, neuroprotetor e farmacêutico, composto, métodos para prevenir ou tratar neuropatia e para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor para proteger um nervo em um mamìfero e para produzir um composto e uso de um composto
AU2003277576A1 (en) 2002-11-08 2004-06-07 Takeda Pharmaceutical Company Limited Receptor function controlling agent
US20070004736A1 (en) 2002-11-22 2007-01-04 Keiji Kubo Imidazole derivative, process for producing the same, and use
WO2004067548A2 (en) 2003-01-31 2004-08-12 Theratechnologies Inc. Chemically modified metabolites of regulatory peptides and methods of producing and using same
US7820837B2 (en) 2003-05-30 2010-10-26 Takeda Pharmaceutical Company Limited Condensed ring compound
EP1670515A2 (en) 2003-09-19 2006-06-21 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
EP1669352A4 (en) 2003-09-30 2008-12-17 Takeda Pharmaceutical THIAZOLINE DERIVATIVE AND ITS USE
WO2005058823A1 (ja) 2003-12-17 2005-06-30 Takeda Pharmaceutical Company Limited ウレア誘導体、その製造法及び用途
US7456218B2 (en) 2003-12-25 2008-11-25 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl) propanoic acid derivatives
WO2005063725A1 (ja) 2003-12-26 2005-07-14 Takeda Pharmaceutical Company Limited フェニルプロパン酸誘導体
WO2005087710A1 (ja) 2004-03-15 2005-09-22 Takeda Pharmaceutical Company Limited アミノフェニルプロパン酸誘導体
JP4859665B2 (ja) 2004-03-30 2012-01-25 武田薬品工業株式会社 アルコキシフェニルプロパン酸誘導体
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
US20060275288A1 (en) 2005-01-20 2006-12-07 Grihalde Nelson D GLP-1 receptor agonist and allosteric modulator monoclonal antibodies and uses thereof
US8957070B2 (en) 2005-04-20 2015-02-17 Takeda Pharmaceutical Company Limited Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity
CA2607566A1 (en) 2005-05-06 2006-11-16 Bayer Pharmaceuticals Corporation Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use
EP1916234B1 (en) 2005-07-29 2014-11-12 Takeda Pharmaceutical Company Limited Cyclopropanecarboxylic acid compound
US20090054435A1 (en) 2005-07-29 2009-02-26 Hiroshi Imoto Phenoxyalkanoic Acid Compound
JP4094660B1 (ja) 2005-08-10 2008-06-04 武田薬品工業株式会社 糖尿病治療剤
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
AU2007265966B2 (en) 2006-06-27 2012-05-17 Takeda Pharmaceutical Company Limited Fused cyclic compounds
JP5399244B2 (ja) 2006-08-17 2014-01-29 アミリン・ファーマシューティカルズ,リミテッド・ライアビリティ・カンパニー 選択可能な特性を持つdpp−iv耐性gipハイブリッドポリペプチド
EP2298772A1 (en) 2006-10-18 2011-03-23 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
CN101573357B (zh) 2006-10-19 2013-01-23 武田药品工业株式会社 吲哚化合物
WO2008093639A1 (ja) 2007-01-29 2008-08-07 Takeda Pharmaceutical Company Limited ピラゾール化合物
AU2008215490A1 (en) 2007-02-09 2008-08-21 Takeda Pharmaceutical Company Limited Fused ring compounds as partial agonists of PPAR-gamma
JPWO2008136428A1 (ja) 2007-04-27 2010-07-29 武田薬品工業株式会社 含窒素5員複素環化合物
EP2157859A4 (en) 2007-06-19 2011-01-12 Takeda Pharmaceutical INDAZOL COMPOUNDS FOR THE ACTIVATION OF GLUCCOKINASE
ES2558842T3 (es) 2008-06-17 2016-02-09 Indiana University Research And Technology Corporation Agonistas mixtos a base de GIP para el tratamiento de trastornos metabólicos y obesidad
US20120148586A1 (en) 2009-08-27 2012-06-14 Joyce Ching Tsu Chou Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
US8426414B2 (en) 2009-10-09 2013-04-23 Bristol-Myers Squibb Company Modulators of G protein-coupled receptor 88
KR20120123443A (ko) 2010-01-27 2012-11-08 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 대사 장애 및 비만 치료용 글루카곤 길항제-gip 항진제 콘쥬게이트
US20120021979A1 (en) 2010-06-24 2012-01-26 Vanderbilt University GLP-1 receptor modulation of addiction, neuropsychiatric disorders and erectile dysfunction
US20150087586A1 (en) 2012-03-29 2015-03-26 Cebix, Inc. Pegylated c-peptide
JP6548579B2 (ja) 2012-12-06 2019-07-24 ヴィクトリア リンク リミテッド コンジュゲート化合物
US9766239B2 (en) 2013-03-13 2017-09-19 Arizona Board Of Regents On Behalf Of Arizona State University Synbodies for detection of human norovirus
CN105555756B (zh) 2013-06-28 2018-12-07 奥克兰联合服务有限公司 氨基酸缀合物和肽缀合物及缀合方法
WO2015031268A1 (en) 2013-08-26 2015-03-05 Arizona Board Of Regents On Behalf Of Arizona State University High affinity synbodies for influenza
WO2016131893A1 (en) 2015-02-18 2016-08-25 Medimmune Limited Incretin fusion polypeptides
GB2551945B (en) 2015-12-18 2021-09-08 Heptares Therapeutics Ltd Novel GLP-1 receptor agonist peptides
MX2020009950A (es) * 2018-03-23 2021-04-28 Carmot Therapeutics Inc Moduladores de receptores acoplados a proteina g.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101420941A (zh) * 2006-04-11 2009-04-29 艾尼纳制药公司 Gpr119受体激动剂用于增加骨质量和用于治疗骨质疏松症的用途,和其相关组合疗法
CN102159566A (zh) * 2008-07-16 2011-08-17 百时美施贵宝公司 作为gpr119调节剂的吡啶酮和哒嗪酮类似物
WO2014074218A1 (en) * 2012-11-12 2014-05-15 Redwood Bioscience, Inc. Compounds and methods for producing a conjugate
US20170326233A1 (en) * 2014-11-14 2017-11-16 Angiochem Inc. Conjugates including an antibody moiety, a polypeptide that traverses the blood-brain barrier, and a cytotoxin
CN105219802A (zh) * 2015-10-10 2016-01-06 广西大学 胰岛组织特异性表达GIPRdn慢病毒载体及其应用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024217497A1 (en) * 2023-04-21 2024-10-24 The University Of Hong Kong Novel small molecule agonists of insulin receptor (insr) as anti-diabetes drugs

Also Published As

Publication number Publication date
IL311177B2 (en) 2026-02-01
JP7526716B2 (ja) 2024-08-01
MX2020009950A (es) 2021-04-28
TW202444405A (zh) 2024-11-16
US20230357347A1 (en) 2023-11-09
EP3768294A1 (en) 2021-01-27
KR102960848B1 (ko) 2026-05-06
UA129084C2 (uk) 2025-01-08
JP2024156720A (ja) 2024-11-06
TW202012432A (zh) 2020-04-01
US11535660B1 (en) 2022-12-27
AR115016A1 (es) 2020-11-18
IL311177A (en) 2024-04-01
WO2019183577A1 (en) 2019-09-26
IL277495A (en) 2020-11-30
US20260176320A1 (en) 2026-06-25
AU2019237507A1 (en) 2020-10-08
JP2021531259A (ja) 2021-11-18
AU2025202679A1 (en) 2025-05-22
KR20260069782A (ko) 2026-05-15
AU2019237507B2 (en) 2025-04-03
IL323264A (en) 2025-11-01
IL277495B1 (en) 2024-04-01
PH12020551539A1 (en) 2021-06-07
BR112020019148A2 (pt) 2021-01-26
SG11202009338SA (en) 2020-10-29
IL277495B2 (en) 2024-08-01
TWI840348B (zh) 2024-05-01
EP3768294A4 (en) 2022-05-04
IL311177B1 (en) 2025-10-01
KR20210008834A (ko) 2021-01-25
MX2025006799A (es) 2025-07-01
CA3094820A1 (en) 2019-09-26
EA202092269A1 (ru) 2020-12-14
MY205468A (en) 2024-10-22

Similar Documents

Publication Publication Date Title
US20230357347A1 (en) Modulators of g-protein coupled receptors
TWI916604B (zh) 作為非全身tgr5促效劑之經取代之4-苯基吡啶化合物
US11555012B2 (en) ACLY inhibitors and uses thereof
US9382197B2 (en) Substituted hydroxamic acids and uses thereof
KR102218771B1 (ko) sGC 자극인자
US20200268897A1 (en) Phosphatase Binding Compounds and Methods of Using Same
TW201639811A (zh) 作為HDAC8抑制劑之α-桂皮醯胺化合物與組成物
IL255580A (en) Nitrogen-containing tricyclic histories have HIV-inhibitory activity
US20260062422A1 (en) Heterobifunctional compounds and methods of treating disease
US20260109707A1 (en) Heterobifunctional compounds and methods of treating disease
TW202417425A (zh) 雌激素受體α降解劑及其使用方法
US20250388605A1 (en) Heterobifunctional compounds and methods of treating disease
US20220249475A1 (en) Compounds and method for treating cytokine release syndrome
EP3192794A1 (en) Sustained hiv protease inhibitor
CN112390852A (zh) 作为蛋白降解剂的化合物及其制备方法和应用
KR20250075580A (ko) 피라졸릴술폰아미드 화합물 및 요법에서 이의 용도
EA051684B1 (ru) Модуляторы сопряженных с g-белком рецепторов
HK40004506A (en) Compounds or pharmacetical salts thereof, as well as uses and pharmceutical compositions thereof
HK1221723B (en) Sgc stimulators

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Country or region after: U.S.A.

Address after: 1600 Amphitheatre Parkway Mountain View California United States 94043

Applicant after: Carmote therapeutics Co.,Ltd.

Address before: California, USA

Applicant before: Carmote therapeutics Co.,Ltd.

Country or region before: U.S.A.